Abstract
We identified a novel mutation of the tumor-associated calcium signal transducer 2 (TACSTD2) gene in a Japanese patient with gelatinous drop-like corneal dystrophy (GDLD). Genetic analysis revealed a novel homozygous mutation (c.798delG, which may result in frameshift mutation p.Lys267SerfsTer4) in the TACSTD2 gene. This mutated gene was devoid of its original function in helping the claudin (CLDN) 1 and 7 proteins transfer from the cytoplasm to the plasma membrane.
Similar content being viewed by others
Introduction
Gelatinous drop-like corneal dystrophy (GDLD; OMIM:204870) is a rare corneal dystrophy. Most affected patients are Japanese, and the estimated incidence is 1/33,000 in Japan1. GDLD is an autosomal recessive disease characterized by the deposition of amyloid in the subepithelial region of the bilateral corneas. As amyloid deposition increases and corneal neovascularization covers the corneal surface, visual acuity becomes severely impaired. Repeated lamellar or penetrating keratoplasty is frequently required for most patients. Using positional cloning, we successfully identified the disease-causing gene, tumor-associated calcium signal transducer 2 (TACSTD2;NM_002353), thereby enabling us to investigate the molecular bases of GDLD2,3,4. To date, 31 different GDLD-causing alterations of the TACSTD2 gene (11 missense, 7 nonsense, and 13 frameshift mutations) have been reported to our knowledge5,6,7,8,9,10,11,12,13,14,15,16. In this study, we identified a novel homozygous frameshift mutation in the TACSTD2 gene in a Japanese family with GDLD and evaluated the pathogenic effect of the mutation.
Materials and methods
All experimental procedures for the sequencing analysis were approved by the Institutional Review Board for Human Studies at Kyoto Prefectural University of Medicine (approval number RBMR-G-148-1). All experimental procedures for the functional analysis were approved by the Institutional Review Board for gene recombination at Osaka University (approval number 2973). Prior informed consent was obtained from the investigated pedigree member after a detailed explanation of the study protocols, and this study was performed in accordance with the tenets of the Declaration of Helsinki for research involving human subjects.
Genomic DNA was extracted from peripheral blood. Polymerase chain reaction (PCR) was performed with a primer pair against TACSTD2 (M1S1-F-2; 5′-CCT GCA GAC CAT CCC AGA C-3′, M1S1-R-2; 5′-CAG GAA GCG TGA CTC ACT TG-3′), which fully covered the coding region of this gene. The PCR product was purified and bidirectionally sequenced using a Big-Dye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Inc., Foster City, CA) in a 20 μl reaction buffer containing a 2× sequencing mixture and either of the above primers. After ethanol precipitation, the sequence products were electrophoresed on an automated capillary sequencer (Genetic Analyzer; Applied Biosystems). To further confirm the mutation detected by the above sequencing analysis, primer extension analysis was performed using a commercial kit (Applied Biosystems, Inc.) for the 798th nucleotide of the TACSTD2 gene coding region in the normal volunteer and patient with the forward primer.
We constructed lentivirus plasmid vectors that harbor the coding region of the CLDN1 or CLDN7 gene. Then, we coinfected HeLa cells not expressing the CLDN1, CLDN7 and TACSTD2 proteins with those lentivirus vectors and used the Tet-on system to overexpress the wild-type or mutant TACSTD2 gene in an inducible manner. First, HeLa cells were seeded at a density of 2.5 × 105 cells per well in a six-well plate and infected with the lentivirus vector expressing the CLDN1 or CLDN7 gene. Four days after the infection, drug selection was performed with 0.5 µg/ml puromycin for 2 weeks. Second, we coinfected those HeLa cells with the lentivirus vector expressing the wild-type or mutated TACSTD2 gene and plenti3.3/TR. Drug selection was performed with 2 µg/ml blasticidin and 500 µg/ml G418 for 2 weeks. The drug-selected HeLa cells, which should express the CLDN1 or CLDN7 genes under the control of the CMV promoter as well as the TACSTD2 gene under the control of a tetracycline-inducible promoter, were seeded on a collagen-coated culture slide (Nunc 177402 Lab-Tek Chamber Slide System with Cover Glass Slide Sterile, Thermo Fisher Scientific Inc.) at a density of 1 × 104 cells per well. Twenty-four hours after seeding, the cells were induced with 1 μg/ml tetracycline for 24 h. After the induction, the cells were fixed with 4% paraformaldehyde, counterstained with Hoechst 33342 dye and mounted with a commercial mounting medium (ProLong® Gold Antifade Mountant, Thermo Fisher Scientific Inc.). The cells were examined under a fluorescent confocal microscope (ELYRA S.1 / LSM710, Carl Zeiss, Oberkochen, Germany) and photographed under the Tet-on system to overexpress the wild-type or mutant TACSTD2 gene.
The patient was a 44-year-old Japanese male at the time of his first admission to our hospital. His parents were first cousins (Fig. 1a). He had already undergone several penetrating keratoplasty (PKP) surgeries prior to admission. Characteristic findings of GDLD, including graft failure, mulberry deposition, and neovascularization, were observed in his left host cornea (Fig. 1b). In his right eye, neovascularization was marked, and the corneal graft was almost covered by the invading conjunctiva (Fig. 1c). He underwent six PKP surgeries, two in his right eye at the ages of 24 and 27 and four in his left eye at the ages of 25, 36, 44, and 50. Currently, his left eye has a best-corrected visual acuity of hand motion, and his right eye is blinded by glaucoma.
Results
Sequencing analysis of the TACSTD2 gene revealed that the patient had a novel homozygous deletion of G at the 798th nucleotide position (c.798delG, Fig. 1d). A single-base primer extension analysis of the 798th nucleotide of the TACSTD2 gene was performed to confirm the above sequence results (Fig. 1e). This mutation caused a premature truncation (p.Lys267SerfsTer4, Fig. 1f) and loss of the transmembrane and PIP2 domains (Fig. 1g). We confirmed that this mutation was not registered in the public SNP databases (ExAC, 1000Genome, HGVD, ToMmo).
In normal corneas, the TACSTD2 protein binds to the CLDN1 and CLDN7 proteins to prevent the degradation of these two molecules. In the absence of functional TACSTD2, the subcellular localization of the CLDN1 and CLDN7 proteins changes from the cell membrane to the intracellular region17. Thus, we examined the subcellular localization of CLDN1 or CLDN7 in the presence of wild-type or p.Lys267SerfsTer4 mutated TACSTD2 using the Tet-on system in HeLa cells that express neither TACSTD2 nor CLDNs. We confirmed the expression of the TACSTD2 protein using the Tet-on system and confirmed cell transfection (data not shown).
Without TACSTD2 expression, we found overexpression of CLDN7 proteins localized at the intracellular region (Fig. 2a, c, e, g). After wild-type TACSTD2 induction, the distribution of CLDN7 was uniformly spread into the plasma membrane (Fig. 2b, f, q). In contrast, p.Lys267SerfsTer4 TACSTD2 induction did not alter the subcellular localization of CLDN7 (Fig. 2d, h, r).
The CLDN1 protein exhibited almost the same pattern as the CLDN7 protein. Without TACSTD2 expression, CLDN1 proteins localized in the intracellular region (Fig. 2i, k, m, o). After wild-type TACSTD2 induction, CLDN1 spread to the plasma membrane (Fig. 2j, n, s). In contrast, the signals were not altered with the mutated TACSTD2 (Fig. 2l, p, t).
These results strongly indicate that the p.Lys267SerfsTer4 mutation is deleterious, causing a change in CLDN localization and tight-junction disruption.
Discussion
The patient demonstrated severe amyloid deposition, corneal neovascularization, and decreased epithelial barrier function, which are the characteristic clinical manifestations of GDLD. Remarkable neovascularization and conjunctival invasion in his right eye occurred presumably as a result of cell cycle acceleration in the limbal cornea. He may present with the typical mulberry-type GDLD18, which is not specific to this mutation19.
The TACSTD2 protein is a type I single transmembrane protein. The mutation examined was a frameshift mutation that led to premature truncation and loss of the transmembrane domain. Therefore, this frameshift mutation was thought to inactivate the TACSTD2 protein. However, the possibility of errors in translation, for example, due to shifts in the reading frame, shunting of ribosomes, or skipping of stop codons, cannot be denied; therefore, we investigated the subcellular localization of CLDN1 and CLDN7 in HeLa cells. From the functional analysis, we concluded that the mutation in TACSTD2 is indeed pathological.
In conclusion, we report a novel homozygous TACSTD2 gene mutation (c.798delG that can result in a frameshift, p.Lys267SerfsTer4) in a Japanese patient with GDLD who was born to a consanguineous couple. Our functional study revealed that the mutation inactivated the TACSTD2 protein, changing the subcellular localization of the CLDN1 and CLDN7 proteins and thereby presumably disrupting the epithelial barrier function of the corneal epithelium.
References
Fujiki, K., Nakayasu, K. & Kanai, A. Corneal dystrophies in Japan. J. Hum. Genet. 46, 431–435 (2001).
Tsujikawa, M. et al. Homozygosity mapping of a gene responsible for gelatinous drop-like corneal dystrophy to chromosome 1p. Am. J. Hum. Genet. 63, 1073–1077 (1998).
Tsujikawa, M. et al. Identification of the gene responsible for gelatinous drop-like corneal dystrophy. Nat. Genet. 21, 420–423 (1999).
Malthiery, Y. & Lissitzky, S. Primary structure of human thyroglobulin deduced from the sequence of its 8448-base complementary DNA. Eur. J. Biochem. 165, 491–498 (1987).
Yoshida, S. et al. Two brothers with gelatinous drop-like corneal dystrophy at different stages of the disease: role of mutational analysis. Am. J. Ophthalmol. 133, 830–832 (2002).
Ha, N. T., Fujiki, K., Hotta, Y., Nakayasu, K. & Kanai, A. Q118X mutation of M1S1 gene caused gelatinous drop-like corneal dystrophy in a family with gelatinous drop-like corneal dystrophy. Am. J. Ophthalmol. 130, 119–120 (2000).
Ren, Z. et al. Allelic and locus heterogeneity in autosomal recessive gelatinous drop-like corneal dystrophy. Hum. Genet. 110, 568–577 (2002).
Fujiki, K., Nakayasu, K. & Kanai, A. Corneal dystrophies in Japan. J. Hum. Genet. 46, 431–435 (2001).
Tian, X. et al. Compound heterozygous mutations of M1S1gene in gelatinous drop-like corneal dystrophy. Am. J. Ophthalmol. 137, 567–569 (2004).
Alavi, A. et al. Four mutations (three novel, one founder) in TACSTD2 among Iranian GDLD patients. Invest. Ophthalmol. Vis. Sci. 48, 4490–4497 (2007).
Markoff, A. et al. A novel TACSTD2 gene mutation in a Turkish family with a gelatinous drop-like corneal dystrophy. Mol. Vis. 12, 1473–1476 (2006).
Taniguchi, Y. et al. A novel missense mutation in a Japanese patient with gelatinous drop-like corneal dystrophy. Am. J. Opthalmol. 139, 186–188 (2005).
Murakami, A., Kimura, S., Fujiki, K., Fujimaki, T. & Kanai, A. Mutations in the membrane component, chromosome 1, surfacemarker1 (M1S1) gene in gelatinous drop-like corneal dystrophy. Jpn. J. Ophthalmol. 48, 317–320 (2004).
Ha, N. T. et al. A novel mutation of M1S1 gene found in a Vietnamese patient with gelatinous drop-like corneal dystrophy. Am. J. Ophthalmol. 135, 390–393 (2003).
Tasa, G. et al. A novel mutation in the M1S1 gene responsible for gelatinous drop-like corneal dystrophy. Invest. Ophthalmol. Vis. Sci. 42, 2762–2764 (2001).
Nakatsukasa, M. et al. Two novel mutations of TACSTD2 found in three Japanese gelatinous drop-like corneal dystrophy families with their aberrant subcellular localization. Mol. Vis. 17, 965–970 (2011).
Nakatsukasa, M. et al. Tumor-associated calcium signal transducer2 is required for the proper subcellular localization of claudin1 and 7: implications in the pathogenesis of gelatinous drop-like corneal dystrophy. Am. J. Pathol. 177, 1344–1355 (2010).
Kinoshita, S., Kawasaki, S., Kitazawa, K. & Shinomiya, K. Establishment of a human conjunctival epithelial cell line lacking the functional TACSTD2 gene (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc. 110, 166–177 (2012).
Ide, T. et al. A spectrum of clinical manifestations of gelatinous drop-like corneal dystrophy in Japan. Am. J. Ophthalmol. 137, 1081–1084 (2004).
Acknowledgements
This work was supported by JSPS KAKENHI Grant Number JP 17K11448 (to M.T.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Nagahara, Y., Tsujikawa, M., Takigawa, T. et al. A novel mutation in gelatinous drop-like corneal dystrophy and functional analysis. Hum Genome Var 6, 33 (2019). https://doi.org/10.1038/s41439-019-0060-z
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41439-019-0060-z